M1 Kliniken AGSTU:M12 +1.55%92 EBITDA Margin % is 11.19% as of Dec. 2025, which is 7% above its 10-year median of 10.48. GuruFocus rates STU:M12 with a GF Score™ of 92/100 and a GF Value™ of €15.98 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, M1 Kliniken AG ranks better than 75.63% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. M1 Kliniken AG's EBITDA for the
six
months ended in Dec. 2025 was €20.2 Mil. M1 Kliniken AG's Revenue for the
six
months ended in Dec. 2025 was €180.8 Mil. Therefore, M1 Kliniken AG's EBITDA margin for the quarter that ended in Dec. 2025 was 11.19%.
M1 Kliniken AG (STU:M12) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
M1 Kliniken AG EBITDA Margin % Related Terms
M1 Kliniken AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for M1 Kliniken AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:M12 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, M1 Kliniken AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M1 Kliniken AG EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, M1 Kliniken AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where M1 Kliniken AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
M1 Kliniken AG (STU:M12) has a EBITDA Margin % of 11.19% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on M1 Kliniken AG and its competitors. This is near median its historical median of 10.48. Over the past decade, M1 Kliniken AG's EBITDA Margin % has ranged from 6.00 to 21.35. According to the industry distribution chart, M1 Kliniken AG ranks #29 out of 119 companies in the Medical Distribution industry, placing it in the top 24.4%.
Is M1 Kliniken AG's EBITDA Margin % too high?
M1 Kliniken AG's current EBITDA Margin % of 11.19% is near median its 10-year median of 10.48. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 21.35. The Medical Distribution industry median EBITDA Margin % is 4.31. M1 Kliniken AG's value of 11.19% is 159.6% above this industry median. Based on the distribution chart, M1 Kliniken AG ranks #29 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, M1 Kliniken AG has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does M1 Kliniken AG's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, M1 Kliniken AG ranks #29 out of 119 companies for EBITDA Margin %. This places M1 Kliniken AG in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.31. M1 Kliniken AG's value of 11.19% is 159.6% above this benchmark. Historically, M1 Kliniken AG's own EBITDA Margin % has ranged from 6.00 to 21.35 over the past decade. While the company's 10-year median is 10.48 vs. the industry median of 4.31, M1 Kliniken AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M1 Kliniken AG's current EBITDA Margin % of 11.19% is 159.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on M1 Kliniken AG and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M1 Kliniken AG's current EBITDA Margin % is 11.19%, which is near median its own 10-year median of 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M1 Kliniken AG stock overvalued right now?
Based on GuruFocus' analysis, M1 Kliniken AG (STU:M12) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.98, compared to a current price of €18.30 — trading 14.5% above its estimated fair value. The current EBITDA Margin % is 11.19%, which is near median its 10-year median of 10.48 and 159.6% above the Medical Distribution industry median of 4.31. M1 Kliniken AG's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For M1 Kliniken AG (STU:M12), the current EBITDA Margin % is 11.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M1 Kliniken AG (STU:M12) Overvalued in 2026?
Based on GuruFocus' analysis, M1 Kliniken AG stock appears to be overvalued.
The current stock price of €18.30 is trading 14.5% above its estimated GF Value™ of €15.98.
GuruFocus considers M1 Kliniken AG to be Modestly Overvalued.
Key valuation signals for STU:M12:
EBITDA Margin %: 11.19% (near median its 10-year median of 10.48)
GF Value™: €15.98 vs. price of €18.30 (14.5% above fair value)
Industry Position: 159.6% above the Medical Distribution median (#29 of 119)
No single metric tells the full story. See the STU:M12 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M1 Kliniken AG operates in the growing market of aesthetic medicine and plastic surgery and provides aesthetic medical treatments in the self-pay segment. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
92GF Score
Get the complete analysis for STU:M12
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:M12 has been successfully added to your 
